A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

October 2, 2023

Study Completion Date

February 26, 2024

Conditions
Cutaneous Lichen Planus
Interventions
DRUG

Ruxolitinib cream

Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

DRUG

Vehicle cream

Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.

Trial Locations (24)

10128

OPTISKIN, New York

20850

Dermassociates, Rockville

35244

Cahaba Dermatology, Birmingham

43209

Bexley Dermatology, Bexley

43213

Clinohio Research Services, Columbus

44124

Apex Clinical Research Center, Mayfield Heights

46250

Dawes Fretzin Clinical Research Group Llc, Indianapolis

55112

Minnesota Clinical Study Center, New Brighton

60077

Northshore Medical Group Dermatology Skokie, Skokie

70115

Delricht Research - Touro Medical Center, New Orleans

70809

Delricht Clinical Research-Clinedge-Ppds Baton Rouge, Baton Rouge

73071

Central Sooner Research, Norman

78660

Austin Institute For Clinical Research Aicr Pflugerville, Pflugerville

84107

University of Utah Health Care Midvalley Health Center Dermatology, Murray

85006

Medical Dermatology Specialists Phoenix, Phoenix

85259

Mayo Clinic Arizona, Scottsdale

89148

Jdr Dermatology Research, Las Vegas

90056

Wallace of Beverly Hills, Los Angeles

97223

Oregon Medical Research Center, Portland

19104-5160

University of Pennsylvania-Perelman School of Medicine, Philadelphia

37130-2450

International Clinical Research Ic Research Murfreesboro, Murfreesboro

76011-3800

Arlington Center For Dermatology, Arlington

R3M 3Z4

Wiseman Dermatology Research Inc, Winnipeg

L3Y 5G8

Dr. S. K. Siddha Medicine Professional Corporation, Newmarket

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY